Interestingly, ASCT2 expression significantly increased in patients with recurrent prostate cancer (p < 0.001; Figure 1C), indicating either re‐activation of androgen receptor signalling or that other signalling pathways might up‐regulate ASCT2 expression upon disease recurrence. This evidence concerns the gene SLC1A5 and prostate carcinoma.